Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider the use of unilateral or bilateral fully or partially implantable bone-conduction (bone-anchored) hearing aid(s) as an alternative to air-conduction hearing aid in patients with a conductive or mixed hearing loss to be eligible for coverage.

Patient Selection Criteria
Coverage eligibility for the use of unilateral or bilateral fully or partially implantable bone-conduction (bone-anchored) hearing aids as an alternative to an air-conduction hearing aid in patients 5 years of age and older with a conductive or mixed hearing loss will be considered when at least 1 of the following criteria are met:

- Congenital or surgically induced malformations (e.g., atresia) of the external ear canal or middle ear; OR
- Chronic external otitis or otitis media; OR
- Tumors of the external canal and/or tympanic cavity; OR
- Dermatitis of the external canal AND

Meet the following audiologic criteria:

- A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kilohertz (kHz) of better than or equal to 45 decibel (dB) (OBC and BP100 devices), 55 decibel (dB) (Intenso device) or 65 decibel (dB) (Cordele II device).
- For bilateral implantation, patients should meet the above audiologic criteria, and have a symmetrically conductive or mixed hearing loss as defined by a difference between left and right side bone conduction threshold of less than 10 decibel (dB) on average measured at 0.5, 1, 2 and 3 kilohertz (kHz), (4 kHz for OBC and Ponto Pro) or less than 15 decibel (dB) at individual frequencies.

When Services Are Eligible for Coverage
Based on review of available data, the Company may consider an implantable bone-conduction (bone-anchored) hearing aid as an alternative to an air-conduction contralateral routing of signal hearing aid in patients five years of age and older with single-sided sensorineural deafness and normal hearing in the other ear. The pure tone average air conduction threshold of the normal ear should be better than 20 decibel (dB) measured at 0.5, 1, 2, and 3 kilohertz (kHz) to be eligible for coverage.
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers other uses of implantable bone-conduction (bone-anchored) hearing aids, including use in patients with bilateral sensorineural hearing loss, to be investigational.*

Based on review of available data, the Company considers implantable bone conduction hearing aids when patient selection criteria are not met to be investigational.*

Background/Overview

Hearing loss is described as conductive, sensorineural, or mixed and can be unilateral or bilateral. Normal hearing is the detection of sound at or below 20 dB. The American Speech-Language-Hearing Association has defined the degree of hearing loss based on pure-tone average (PTA) detection thresholds as mild (20-40 dB), moderate (40-60 dB), severe (60-80 dB), and profound (≥80 dB). PTA is calculated by averaging the hearing sensitivities (ie, the minimum volume that the patient hears) at multiple frequencies (perceived as pitch), typically within the range of 0.25 to 8 kHz.

Sound amplification through the use of an AC hearing aid can provide benefit to patients with sensorineural or mixed hearing loss. Contralateral routing of signal (CROS) is a system in which a microphone on the affected side transmits a signal to an AC hearing aid on the normal or less affected side.

Bone-Conduction Hearing Devices

External bone-conduction hearing aids function by transmitting sound waves through the bone to the ossicles of the middle ear. The external devices must be closely applied to the temporal bone, with either a steel spring over the top of the head or with the use of a spring-loaded arm on a pair of spectacles. These devices may be associated with either pressure headaches or soreness.

The bone-anchored hearing aid (BAHA) implant system works by combining a vibrational transducer coupled directly to the skull via a percutaneous abutment that permanently protrudes through the skin from a small titanium implant anchored in the temporal bone. The system is based on the process of osseointegration through which living tissue integrates with titanium in the implant over a period of 3 to 6 months, allowing amplified and processed sound to be conducted via the skull bone directly to the cochlea. The lack of intervening skin permits the transmission of vibrations at a lower energy level than required for external bone-conduction hearing aids. Implantable bone-conduction hearing systems are primarily indicated for people with conductive or mixed sensorineural/conductive hearing loss, or as an alternative to an AC hearing aid with CROS for individuals with unilateral sensorineural hearing loss.

Partially implantable magnetic bone-conduction hearing systems are available as an alternative to bone-conduction hearing systems connected percutaneously via an abutment. With this technique, acoustic transmission occurs transcutaneously via magnetic coupling of the external sound processor and the internally implanted device components. The bone-conduction hearing processor contains magnets that
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy #  00004
Original Effective Date:  06/24/2002
Current Effective Date:  10/19/2016

adhere externally to magnets implanted in shallow bone beds with the bone-conduction hearing implant. Because the processor adheres magnetically to the implant, there is no need for a percutaneous abutment to physically connect the external and internal components. To facilitate greater transmission of acoustics between magnets, skin thickness may be reduced to 4 to 5 mm over the implant when it is surgically placed.

**FDA or Other Governmental Regulatory Approval**
U.S. Food and Drug Administration (FDA)

There are 5 BAHA‡ sound processors for use with the BAHA auditory osseointegrated implant system manufactured by Cochlear Americas (Englewood, CO) that have received 510(k) clearance from FDA:
- BAHA Cordelle II
- BAHA Divino
- BAHA Intenso (digital signal processing)
- BAHA BP100
- BAHA 4 (upgraded from the BP100)

FDA cleared the BAHA system for the following indications:
- Patients who have conductive or mixed hearing loss and can still benefit from sound amplification;
- Patients with bilaterally symmetric conductive or mixed hearing loss, may be implanted bilaterally;
- Patients with sensorineural deafness in 1 ear and normal hearing in the other (ie, single-sided deafness, SSD);
- Patients who are candidates for an air-conduction contralateral routing of signals (AC CROS) hearing aid but who cannot or will not wear an AC CROS device.

The BAHA implant is cleared for use in children aged 5 years and older, and in adults.

BAHA sound processors can also be used with the BAHA Softband™. With this application, there is no implantation surgery. The sound processor is attached to the head using either a hard or soft headband. The amplified sound is transmitted transcutaneously to the bones of the skull for transmission to the cochlea. The BAHA Softband received FDA clearance in 2002 for use in children younger than 5 years. As this application has no implanted components, it is not addressed in the policy.

In November 2008, the device “OBC Bone Anchored Hearing Aid System” (Oticon Medical, Kongebakken, Denmark) was cleared by FDA for marketing through the 510(k) process. Subsequently, additional bone-conduction hearing systems have received 510(k) marketing clearance from FDA including Otomag™ (Sophono Inc., Boulder, CO) and Ponto™ (Oticon Medical). The Ponto Pro processor can be used with the Oticon or BAHA implants. In May 2011, Sophono Inc. and Oticon Medical partnered to receive 510(k) marketing clearance from FDA for the Otomag Alpha 1(M), a partially implantable bone-conduction hearing system. All of these devices were determined to be substantially equivalent to existing devices (eg, the Xomed Audiant™, which was FDA cleared for marketing in 1986 but is no longer available). They share similar indications as the Cochlear Americas BAHA devices.
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy #: 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

The 2 partially implantable magnetic bone-conduction devices that have received 510(k) clearance from FDA are:

- Otomag Bone Conduction Hearing System (Sophono Inc., Boulder, CO), and
- Cochlear BAHA Attract (Cochlear Americas, Centennial, CO)

The BoneBridge™ (MedEl, Innsbruck, Austria) is another partially implantable bone-conduction implant that is cleared for marketing in Europe but has not received FDA approval for use in the United States.

The SoundBite™ Hearing System (Sonitus Medical, San Mateo, CA) is an intraoral bone-conducting hearing prosthesis that consists of a behind-the-ear microphone and an in-the-mouth hearing device and was cleared for marketing through FDA’s 510(k) clearance process in 2011 for similar indications as the BAHA. Because this system has no implanted components, it is not addressed in the current policy. As of January 2015, Sonitus Medical is in bankruptcy.

FDA product code (for bone-anchored hearing aid): LXB.

FDA product code (for implanted bone-conduction hearing aid): MAH.

Centers for Medicare and Medicaid Services (CMS)
No national coverage determination. The Medicare Benefit Policy Manual references hearing aids and auditory implants, stating that hearing aids are excluded from coverage, including air-conduction and bone-conduction devices. However, devices which produce the perception of sound by replacing the function of the middle ear, cochlea, or auditory nerve are payable by Medicare as prosthetic devices. These devices are indicated only when hearing aids are medically inappropriate or cannot be utilized. Along with cochlear and auditory brainstem implants, the benefit manual specifically refers to osseointegrated implants as prosthetic devices. In 2014, Medicare clarified its hearing aid coverage to state that certain auditory implants, including cochlear implants, brain stem implants, and osseointegrated implants, do not meet the definition of hearing aids that are excluded from coverage.

Rationale/Source
The evidence related to the use of BAHA devices is characterized by observational studies that report pre- and postimplant hearing outcomes in patients treated with BAHA. Many of these studies combine patients with differing underlying disease states and indications. No randomized controlled trials (RCTs) have compared implantable bone-conduction hearing aids to other hearing augmentation devices, or sham devices. Following is a summary of key findings.

Overall Efficacy of BAHAs

Systematic Reviews and Meta-Analyses
Two systematic reviews by the Health Technology Assessment Program were published in 2011 on the use of BAHAs for bilateral hearing impairment. The quality of available studies on the use of BAHAs was weak. No studies with control groups were identified. Cohort pre-post studies and cross-sectional comparative studies demonstrated improvements in hearing with use of BAHAs over conventional bone-conduction
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

hearing aids or unaided hearing. However, whether improvements in hearing with BAHAs were greater than with air-conduction (AC) hearing aids was uncertain. Additionally, bilateral use of BAHAs improved hearing outcomes in some patients over unilateral use, but that evidence, too, was uncertain. Implant loss ranged between 6.1% and 19.4%. The authors noted that hearing-specific quality of life (QOL) improved, but overall QOL did not differ.

Observational Studies
Since the publication of the Health Technology Assessment Program systematic review, a number of observational studies have evaluated specific aspects of BAHA implantation or reported outcomes in specific populations. Several observational studies have suggested that newer generation BAHAs with fully digital signal processors improve hearing to a greater degree than earlier generation devices.

In 2014, Farnoush et al retrospectively compared BAHA placement with reconstruction of the external auditory canal for children and adolescents with congenital aural atresia or stenosis who were treated at a single institution from 1988 to 2011. Sixty-eight patients were included, 49 who underwent external auditory canal reconstruction (EACR) and 19 who received a BAHA. Groups differed significantly in terms of age, presence of bilateral atresia, and presence of an associated syndrome. Audiologic data were available for 41 patients. At short-term (<6 months postsurgery) follow-up, the BAHA group had larger hearing gains on AC than the EACR group (44.3 dB vs 20.0 dB; p<0.001); similarly, the BAHA group had larger hearing gains at long term (>1 year postsurgery) follow-up (44.5 dB vs 15.3 dB; p<0.001). Quality-of-life scores and requirements for revision surgery did not differ significantly between the groups.

In 2011, Ramakrishnan et al retrospectively reviewed bone-anchored and Softband-held conductive hearing aids in 109 children and young adults in a single center. The patient population was unique in that many had craniofacial or genetic syndromes and hearing loss (22/109). Criteria for selection of the implanted device or the Softband were not described, though authors noted an uneven distribution by age, sex, and syndromic comorbidity. Primary measures were the Glasgow Benefit Inventory or Listening Situation Questionnaire (parent version) administered at least 3 months after hearing aid intervention. Mean overall Glasgow Benefit Inventory scores were +29 (range, 11-72). Mean Listening Situation Questionnaire score was 17, which was less than a referral cutoff of 22. Based on mean scores, authors concluded that this population benefitted from bone-anchored and Softband-held conductive hearing aids. Conclusions were affected by the heterogeneous patient population, lack of preintervention measures, and lack of a controlled comparator group. Other series describing outcomes for pediatric patients treated with bone-anchored devices have reported a benefit in hearing scores, including den Besten et al (2015) in 79 children ages 17 and under.

Older case series have reported patient-reported benefits and satisfaction after BAHA placement. Some have suggested that the BAHA improved hearing better than early bone-conducting devices and AC hearing aids and produced acceptable hearing outcomes in individuals unable to tolerate an AC hearing aid.
Efficacy of Bilateral BAHA Devices in Conductive or Mixed Hearing Loss
A number of studies have demonstrated a consistent improvement in speech recognition in noise and in sound localization using bilateral devices for people with conductive (CHL) or mixed hearing loss.

Janssen et al (2012) conducted a systematic review to assess the outcomes of bilateral versus unilateral BAHA for individuals with bilateral permanent CHL. Their search strategy included studies of all languages published between 1977 and July 2011. Studies were included if subjects of any age had permanent bilateral CHL and bilateral implanted BAHAs. Outcome measures of interest were any subjective or objective audiologic measures, quality-of-life indicators, or reports of adverse events. Eleven studies met their inclusion criteria. All 11 studies were observational. There were a total of 168 patients in the 11 studies, 155 of whom had BAHAs and 146 of whom had bilateral BAHAs. In most studies, comparisons between unilateral and bilateral BAHA were intrasubject. Patients ranged from 5 to 83 years of age; 46% were male, and 54% were female. Heterogeneity of the methodologies between studies precluded meta-analysis, therefore a qualitative review was performed. Results from 3 (of 11) studies were excluded from synthesis because their patients had been included in multiple publications. Adverse events were not an outcome measure of any of the included studies. In general, bilateral BAHA was observed to provide additional objective and subjective benefit compared with unilateral BAHA. For example, the improvement in tone thresholds associated with bilateral BAHA ranged from 2 to 15 dB, the improvement in speech recognition patterns ranged from 4 to 5.4 dB, and the improvement in the Word Recognition Score ranged from 1% to 8%. However, these results were based on a limited number of small observational studies consisting of heterogeneous patient groups that varied in age, severity of hearing loss, etiology of hearing loss, and previous amplification experience.

Examples of individual studies include the following. In 2001, Bosman et al reported on findings from 25 patients who were using bilateral devices. They found that both speech recognition in noise and directional hearing improved with the second device. In a 2004 publication, Priwin et al reported similar findings in 12 patients with bilateral devices. A consensus statement published in 2005 concluded that bilateral devices resulted in binaural hearing with improved directional hearing and improved speech-in-noise scores in those with bilateral CHL and symmetric bone-conduction thresholds. A number of additional studies that are cited in this report found benefits similar to those noted in the studies of the Bosman et al and Priwin et al reports. Positive outcomes continue to be reported: Dun et al (2010) identified improvements in the Glasgow Benefit Inventory in children (n=23), while Ho et al (2009) reported the same benefit in adults (n=93).

Efficacy of BAHA Devices for Unilateral Sensorineural Hearing Loss
In 2015, Peters et al reported results from a systematic review of studies comparing BAHA devices with contralateral routing of signal (CROS) systems to hearing aids with CROS for single-sided deafness (SSD). Six studies met eligibility criteria, including 1 RCT and 3 prospective and 2 retrospective case series, 5 of which were considered to have moderate-to-high directness of evidence and low-to-moderate risk of bias. The 5 studies with low or moderate risk of bias included a total of 91-patients; they were noted to have significant heterogeneity in the populations included. For speech perception in noise, there was no consistent improvement with aided hearing over unaided hearing in all environments. All studies reported equal sound localization and QOL outcomes for both hearing conditions.
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

Baguley et al (2006) reviewed the evidence for contralateral BAHAs in adults with acquired unilateral sensorineural hearing loss. None of the 4 controlled trials reviewed showed a significant improvement in auditory localization with the bone-anchored device. However, speech discrimination in noise and subjective measures improved with these devices; for these parameters, the BAHAs resulted in greater improvement than that obtained with the conventional AC CROS systems.

Since publication of the Peters systematic review, 1 prospective, interventional study compared patient satisfaction with transcutaneous BAHA devices to CROS hearing aids for SSD. Letterme et al assessed 24 adults with SSD, 18 of whom were evaluated with trials of both hearing aids with CROS and bone conduction–assisted hearing using the Baha Softband. Most (72%) patients, after completing trials of both devices, preferred the BAHA device to hearing aid with CROS. Glasgow Benefit Inventory and Abbreviated Profile of Hearing Aid Benefit (APHAB) scores did not differ significantly between devices. Sixteen of the 18 subjects elected to undergo implantation of a percutaneous BAHA device. In general, hearing improvement with the Baha Softband trial correlated with hearing improvements following device implantation.

Several centers have reported on findings from observational studies that evaluated the benefits of BAHA for patients with unilateral SSD. Most of these studies were retrospective. Studies representative of this group are described next.

Zeitler et al (2012) reported on a retrospective case series of 180 patients with SSD and residual hearing in the implanted ear who underwent unilateral or bilateral BAHA placement at a U.S. university medical center. Significant improvement was reported in objective hearing measures (speech-in-noise and monosyllabic word tests) following BAHA implantation. Subjective benefits from BAHA varied across patients based on results from the Glasgow Hearing Aid Benefit Profile, but patients with residual hearing in the affected ear tended toward improved satisfaction with their device postoperatively.

Additional series from various countries, with sample sizes ranging from 9 to 145 patients, have reported on outcomes after implantation of BAHA device for SSD. In general, these studies have indicated improvements in patient-reported speech quality, speech perception in noise, and patient satisfaction.

Efficacy of BAHA Devices in Children Younger Than Age 5 Years

The BAHA device has been investigated in children younger than 5 years in Europe. A number of reports have described experience with preschool children or children with developmental issues that might interfere with device maintenance and skin integrity. A 2-stage procedure may be used in young children. In the first stage, the fixture is placed into the bone and allowed to fully osseointegrate. After 3 to 6 months, a second procedure is performed to connect the abutment through the skin to the fixture.

The largest series in children under 5 years we identified, described by Amonoo-Kuofi et al (2015), included 24 children identified from a single center’s prospectively maintained database. Most patients underwent a 2-stage surgical approach. Most (52%) patients received the implant for isolated microtia or Goldenhar syndrome (16%). Following implantation, 13 (54%) patients had grade 2 or 3 local reactions assessed on the Holgers Scale (redness, moistness, and/or granulation tissue) and 7 (29%) had grade 4 local reactions on this scale (extensive soft-tissue reaction requiring removal of the abutment). QOL scores (Glasgow...
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy #   00004
Original Effective Date:  06/24/2002
Current Effective Date:  10/19/2016

Children’s Benefit Inventory; scoring range, -100 to 100) were obtained in 18 subjects/parents, with a finale mean score change of +40 points. Audiologic testing indicated that the average performance of the device fell within the range of normal auditory perception in noisy and quiet environments.

Marsella et al (2012) have reported on their center’s experience in Italy with pediatric BAHA from the inception of their program in 1995 to December 2009. A total of 47 children (21 females, 26 males) were implanted; 7 of these were younger than 5 years. The functional gain was significantly better with BAHA than with conventional bone-conduction hearing aids, and there was no significant difference in terms of functional outcome between the 7 patients receiving a BAHA at an age younger than 5 years and the rest of the patient cohort. Based on these findings, the study authors suggested that implantation of children at an age younger than 5 years can be conducted safely and effectively in such settings. The conclusions are limited by the small number of children younger than 5 years of age in the study and the limited power to detect a difference between younger and older children.

Davids et al (2007) at the University of Toronto provided BAHA devices to children younger than 5 years of age for auditory and speech-language development and retrospectively compared surgical outcomes for a study group of 20 children younger than 5 years and a control group of 20 older children. Children with cortical bone thickness greater than 4 mm underwent a single-stage procedure. The interstage interval for children having 2-stage procedures was significantly longer in the study group to allow implantation in younger patients without increasing surgical or postoperative morbidity. Two traumatic fractures occurred in the study group versus 4 in the older children. Three younger children required skin site revision. All children were wearing their BAHA devices at the time of writing. McDermott et al (2008) reported on the role of BAHAs in children with Down syndrome in a retrospective case analysis and postal survey of complication rates and quality-of-life outcomes for 15 children aged 2 to 15 years. All patients were using their BAHA devices after a 14-month follow-up. No fixtures were lost; skin problems were encountered in 3 patients. All 15 patients had improved social and physical functioning, attributed to improved hearing.

Safety and Adverse Events Related to Bone-Anchored Hearing Aids

In addition to the literature evaluating the effectiveness of BAHA devices in improving hearing, a number of studies have evaluated or reported specifically on complications related to BAHAs.

In 2013, Kiringoda et al reported on a meta-analysis of complications related to BAHA implants. Included in the meta-analysis were 20 studies that evaluated complication in 2134 adult and pediatric patients who received a total of 2310 BAHA implants. While the quality of available studies was considered poor and lacking in uniformity, complications related to BAHA implants were mostly minor skin reactions. The incidence of Holgers grade 2 to 4 skin reactions was 2.4% to 38.1% in all studies (grade 2, red and moist tissue; grade 3, granulation tissue; and grade 4, infection leading to removal of the abutment). The incidence of failed osseointegration was 0% to 18% in adult and mixed population studies and 0% to 14.3% in pediatric population studies. The incidence of revision surgery was 1.7% to 34.5% in adult and mixed population studies and 0.0% to 44.4% in pediatric population studies. Implant loss occurred in 1.6% to 17.4% in adult and mixed population studies and in 0.0% to 25% in pediatric studies.
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

In 2012, Dun et al assessed soft tissue reactions and implant stability of 1132 percutaneous titanium implants for bone-conduction devices through a retrospective survey of 970 patients undergoing implants between September 1988 and December 2007 at the University Medical Center in the Netherlands. Study investigators also examined device usage and comparisons between different patient age groups (children, adults, elderly patients) over a 5-year follow-up period. Implant loss was 8.3%. In close to 96% of cases, there were no adverse soft tissue reactions. Significantly more soft tissue reactions and implant failures were observed in children compared with adults and elderly patients (p<0.05). Implant survival was less in patients with mental retardation compared with patients without mental retardation (p=0.001).

In 2010, Hobson et al reviewed complications of 602 patients at a tertiary referral center over 24 years and compared their observed rates to those published in 16 previous studies. The overall observed complication rate of 23.9 % (144/602) is similar to other published studies (complication rate, 24.9%±14.85). The most common complications were soft tissue overgrowth, skin infection, and fixture dislodgement. The observed rate of revision surgery of 12.1% (73/602) was also similar to previously published rates of 12.7%. Top reasons for revision surgery were identical to observed complications. In 2011, Wallberg et al reported on the status of 150 implants placed between 1977 and 1986 and followed for a mean of 9 years. Implants were lost in a total of 41 patients (27%). Reasons for implant loss were: removal in 16 patients, osseointegration failure in 17 patients, and direct trauma in 8 patients. In the remaining 132 patients with implant survival, BAHAs were still being used by 119 patients (90%) at the end of follow-up. For children, implant complications were even more frequent, as reported by Kraai et al (2011) in a follow-up evaluation of 27 implants placed in children ages 16 years or younger between 2002 and 2009. In this retrospective report, soft tissue reactions occurred in 24 patients (89%); removal of the implant or revision surgery was required in 10 patients (37%); 24 patients (89%) experienced soft tissue overgrowth and infection; and 7 patients (26%) experienced implant trauma. Chronic infection and overgrowth at the abutment prevented use of the implant in 3 patients (11%).

In 2014, Allis et al conducted a prospective observational cohort study with a retrospective historical control to evaluate complication rates of skin overgrowth, infection, and the need for revision surgery associated with a BAHA implant with a longer (8.5-mm) abutment. Twenty-one subjects were treated with the 8.5-mm abutment implant from 2011 to 2012 and were compared to 23 subjects treated with a 5.5-mm abutment implant from 2010 to 2011. Groups were generally similar at baseline, except that patients with the 8.5-mm abutment implant were older (62 years vs 48 years, p=0.012). Patients in the longer abutment group were less likely to experience infection (10% vs 43%; p=0.02), skin overgrowth (5% vs 41%; p=0.007), and need for revision (10% vs 45%; p=0.012), respectively.

Other observational cohort studies, ranging in size from 47 to 974 subjects, have reported safety and adverse effects outcomes after BAHA placement. Across these studies, implant loss ranged from 4% to 18%.

Different surgical techniques for implanting BAHA devices and specific BAHA designs have yielded better safety outcomes. In a systematic review of 30 articles on the association between surgical technique and skin complications following BAHA implantation, the dermatome technique (vs a skin graft or linear technique) was linked to more frequent skin complications. Fontaine et al (2014) compared complication
rates for 2 Baha surgical implantation techniques among 32 patients treated from 2004 to 2011. Complications requiring surgical revision occurred in 20% of cases who had a skin flap implantation method \((n=20)\) and in 38% of cases who had a full-thickness skin graft implantation method \((n=21); p=0.31\). Hultcrantz and Lanis (2014) reported shorter surgical times and fewer cases of numbness and peri-implant infections in 12 patients treated with a non-skin-thinning technique, compared with 24 patients treated with a flap or a dermatome implantation technique. In a comparison of 2 types of Baha devices, one with a 4.5-mm diameter implant with a rounded 6-mm abutment \((n=25)\) and one with a 3.75-mm diameter implant with a conically shaped 5.5-mm abutment \((n=52)\), Nelissen et al (2014) reported that implant survival was high for both groups over a 3-year follow-up, although the conically shaped abutment had greater stability. Singam et al (2014) reported results of a Baha implantation technique without soft tissue reduction in conjunction with a longer device abutment in 30 patients. Twenty-five patients had no postoperative complications. Five subjects developed postoperative skin reactions, of whom 3 required soft tissue reduction.

**Partially Implantable Magnetic Bone-Conduction Hearing Aids**
A smaller body of literature addresses outcomes associated with transcutaneous, partially implantable bone-anchored devices that magnetically couple the sound processor with the implant. Similar to the literature available for percutaneous bone-anchored devices, most studies use a within-subjects comparison of hearing thresholds with and without the device. The indications for partially implantable systems are the same as those for transcutaneous bone-anchored devices.

**Prospective Trials**
Two prospective trials evaluating different transcutaneous systems were identified. Both trials were small (27 and 15 individuals, respectively), but both demonstrated improvements in hearing outcomes.

Briggs et al (2015) reported on a prospective interventional evaluation of the percutaneous, partially implantable Baha Attract System among 27 adults with a CHL or mild mixed hearing loss in the ear to be implanted. The choice of sound processor was based on patient preference and hearing tests with various sound processors in conjunction with Baha Softband prior to device implantation. All 27 patients enrolled received an implant. Sound processor fitting occurred 4 weeks postimplantation in all but 1 patient. At 9-month follow-up, pure-tone audiometry (means of 500, 1000, 2000, and 4000 Hz) was significantly improved with the implant and sound processor compared with unaided hearing (18.4-dB hearing loss, SD=6.9 dB; \(p<0.001\)). Patients generally showed improvements in speech recognition in noise, although comparing results across test sites was difficult due to different languages and methodologies used for testing speech recognition at each site. Compared with the preoperative unaided state, scores on the APHAB overall score \((p=0.038)\) and reverberation \((p=0.016)\) and background noise \((p=0.035)\) subscales.

Denoyelle et al (2015) reported on a prospective trial of the Sophono device in children ages 5 to 18 years with uni- or bilateral congenital aural atresia with complete absence of the external auditory canal with pure CHL. The study included a within-subject comparison of hearing results with the Sophono devices to those obtained with the Baha Softband preoperatively. All 15 patients enrolled were implanted (median age, 97 months). At 6-month follow-up, mean aided AC pure-tone audiometry was 33.49 (mean gain, 35.53 dB), with a mean aided sound reception threshold of 38.2 (mean gain, 33.47 dB). The difference in AC PTA
between the Baha Softband and the Sophono device was 0.6 dB (confidence interval upper limit, 4.42 dB), which met the study’s prespecified noninferiority margin. Adverse effects were generally mild, including skin erythema in 2 patients, which improved by using a weaker magnet, and brief episodes of pain or tingling in 3 patients.

**Nonrandomized Comparative Studies**

A limited amount of data is available comparing transcutaneous to percutaneous bone-anchored conduction devices. In 2013, Hol et al compared percutaneous BAHA implants to partially implantable magnetic transcutaneous bone-conduction hearing implants using the Otomag Sophono device in 12 pediatric patients (age range, 5-12 years), who had congenital unilateral CHL. Sound-field thresholds, speech recognition threshold, and speech comprehension at 65 dB were somewhat better in patients with the BAHA implant (n=6) than in those with the partially implantable hearing device (n=6). Using a skull simulator, output was 10 to 15 dB lower with the partially implantable device than with the BAHA device.

Iseri et al (2015) described a retrospective, single-center study from Turkey comparing 21 patients treated with a transcutaneous, fully implantable BAHA to 16 patients treated with a percutaneous device (the Baha Attract). Groups were generally similar at baseline, with most individuals undergoing BAHA placement for chronic otitis media. Operating time was longer in patients treated with the transcutaneous partially implantable devices (46 minutes vs 26 minutes, p<0.05). Three patients treated with percutaneous devices had Holgers Scale grade 2 skin reactions and 2 had stopped using their devices for reasons unrelated to skin reactions. Mean thresholds for frequencies 0.5 to 4.0 kHz were 64.4 dB without the BAHA and 31.6 dB with the BAHA in the percutaneous device group, and 58.3 dB without the BAHA and 27.2 dB with the BAHA in the transcutaneous device group. Frequency-specific threshold hearing gains did not differ significantly between groups. Mean hearing gain measured by speech reception threshold was statistically significantly smaller in the percutaneous group (24 dB vs 36.7 dB, p=0.02).

**Observational Studies**

A moderately sized body of observational studies—most at a single center and with fewer than 10 patients—has reported outcomes for transcutaneous, partially implantable hearing systems. These studies are briefly described here to provide an overview of the functional gain and complications seen with the transcutaneously coupled devices.

In an early (2011) study, Seigert reported on the use of a transcutaneous, partially implantable bone-conduction hearing system (Otomag). Among 12 patients who received the system, there were average hearing gains of 31.2 dB in free-field pure-tone audiogram. The free-field suprathreshold speech perception at 65 dB increased from 12.9% preimplantation to 72.1% postimplantation.

Powell et al (2015) reported outcomes from a retrospective study that included 6 patients treated with the Otomag Sophono device and 6 treated with the BAHA Attract device. Ten subjects were identified as the primary author’s patients and the remaining were identified through an Australian national hearing database. In the BAHA Attract group, mean AC thresholds across 4 frequencies (0.5, 1, 2, and 4 kHz) improved from 60.8 dB in the unaided state to 30.6 dB in the aided state. In the Sophono group, the mean
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

4-frequency AC thresholds improved from 57.8 dB in the unaided state to 29.8 dB in the aided state. Speech discrimination in noise scores did not differ significantly between devices.

O’Niel et al (2014) reported outcomes for 10 pediatric patients with CHL treated with the Otomag Sophono device at a single center. Fourteen ears were implanted with no surgical complications. The skin complication rate was 35.7%, including skin breakdown (n=2) and pain and erythema (n=5); negative outcomes resulted in 5 (36%) of 14 ears having sufficient difficulties to discontinue device use for a period. Mean aided PTA was a 20.2-dB hearing level, with a mean functional gain of a 39.9-dB hearing level. Patients without skin complications consistently used their devices (average daily use, 8-10 hours).

Centric et al (2014) also reported outcomes for 5 pediatric patients treated with the Otomag Sophono device at a single center. Etiologies of hearing loss were heterogeneous and included bilateral moderate or severe CHL and unilateral sensorineural hearing loss. Average improvement in PTA was a 32-dB hearing level, and the average improvement in speech response threshold was a 28-dB hearing level. All patients were responding in the normal-to-mild hearing loss range in the implanted ear after device activation. In a follow-up study from the same institution, Baker et al reported pooled outcomes for the first 11 patients treated with the Otomag Sophono and the first 6 patients treated with the Baha Attract. Pre- and postimplant audiometric data were available for 11 ears in the Sophono group and 5 in the Baha Attract group. Average improvement over all frequencies ranged from a 24- to 43-dB hearing level in the Sophono group and from a 32- to 45-dB hearing level in the Baha Attract group. Average improvement in PTA was a 38-dB hearing level in the Sophono group and a 41-dB hearing level in the Baha Attract group.

Other single-center observational series have described clinical experience with transcutaneous partially implantable BAHA devices. Marsella et al (2014) reported outcomes for 6 pediatric patients treated with the Otomag Sophono device for CHL or mixed hearing loss. Median improvement in PTA was 33-dB hearing loss and median free-field PTA (0.5-3 kHz) with the device was 32.5-dB hearing loss. Carr et (2015) reported outcomes for 10 patients treated with the Baha Attract device, most commonly for chronic suppurative otitis media (n=3) and SSD (n=3). Patients did not show significant improvement in word discrimination score. Magliulo et al (2015) reported outcomes for 10 patients treated with the Otomag Sophono device after subtotal petrosectomy for recurrent chronic middle ear disease, a procedure associated with a CHL of 50 to 60 dB. Postsurgery with the Sophono device, there was an average acoustic improvement in AC of 29.7 dB, which was significantly better than the improvement seen with traditional AC hearing aids (18.2 dB).

In addition to studies of partially implantable bone-conduction devices currently approved by the FDA, a number of case series identified evaluated the Bonebridge implant, which is not currently cleared for marketing in the United States. Case series with at least 5 patients are summarized in Table 1.

Table 1: Case Series Evaluating the Bonebridge Implant

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Patient Population</th>
<th>Main Hearing Results</th>
<th>Safety Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rahne et al (2015)</td>
<td>11</td>
<td>• SSD (n=6; 1 sensorineural, 3 mixed, 2 conductive)</td>
<td>• Aided sound-field threshold improvement: 33.4 dB</td>
<td>1 case of chronic fibrosing mastoiditis requiring mastoidectomy and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bilateral CHL (n=2)</td>
<td>• WRS improved from mean of 10% unaided to 87.5% aided</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bilateral mixed hearing loss</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Patient Population</th>
<th>Main Hearing Results</th>
<th>Safety Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laske et al</td>
<td>9</td>
<td>Adults with SSD and normal contralateral hearing</td>
<td>Speech discrimination signal-to-noise improvement for aided vs unaided condition, sound presented to aided ear: 1.7 dB; Positive improvements on quality-of-life questions</td>
<td>Not reported</td>
</tr>
<tr>
<td>(2015)</td>
<td></td>
<td>or mixed/sensorineural (n=3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riss et al</td>
<td>24</td>
<td>Combined hearing loss (n=9)</td>
<td>Average functional gain: 28.8 dB</td>
<td>Not reported</td>
</tr>
<tr>
<td>(2014)</td>
<td></td>
<td>EAC atresia (n=12)</td>
<td>Monosyllabic word scores at 65-dB sound pressure increased from 4.6-53.7 percentage points</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SSD (n=3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manrique</td>
<td>5</td>
<td>Mixed hearing loss (n=4)</td>
<td>PTA improvement: 35.62 dB (p=0.01)</td>
<td>No perioperative complications reported</td>
</tr>
<tr>
<td>et al (2014)</td>
<td></td>
<td>SSD (n=1)</td>
<td>Disyllabic word discrimination improvement: 20% (p=0.016)</td>
<td></td>
</tr>
<tr>
<td>Ihler et al</td>
<td>6</td>
<td>Mixed hearing loss (n=4)</td>
<td>PTA functional gain (average, 0.5-4.0 kHz): 34.5 dB</td>
<td>Prolonged wound healing in 1 case</td>
</tr>
<tr>
<td>(2014)</td>
<td></td>
<td>CHL (n=2)</td>
<td>Speech discrimination at 65 dB:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o In quiet: 63.3 percentage points</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>o In noise: 37.5 percentage points</td>
<td></td>
</tr>
<tr>
<td>Desmet et al</td>
<td>44</td>
<td>All unilaterally deaf adults</td>
<td>Statistically significant improvement on APHAB and SHHIA</td>
<td>Not reported</td>
</tr>
<tr>
<td>(2014)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iseri et al</td>
<td>12</td>
<td>CHL (n=9)</td>
<td>Speech reception threshold increase: 19 dB</td>
<td>Postoperative hematoma requiring aspiration in 1 case</td>
</tr>
<tr>
<td>(2014)</td>
<td></td>
<td>“Primarily conductive hearing loss” (n=3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APHAB: Abbreviated Profile of Hearing Aid Benefit; CHL: conductive hearing loss; EAC: external auditory canal; PTA: pure-tone average; SHHIA: Short Hearing Handicap Inventory for Adults; SSD: single-sided deafness; WRS: word recognition score.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01264510</td>
<td>The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness</td>
<td>150</td>
<td>Aug 2015 (ongoing)</td>
</tr>
<tr>
<td>NCT02022085a</td>
<td>Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)</td>
<td>52</td>
<td>Mar 2017</td>
</tr>
<tr>
<td>NCT01858246</td>
<td>A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge</td>
<td>60</td>
<td>Dec 2017</td>
</tr>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01715948</td>
<td>Comparison of BAHA and CROS Hearing Aid in Single-Sided</td>
<td>9</td>
<td>Oct 2013</td>
</tr>
</tbody>
</table>
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

Summary of Evidence
For individuals who have conductive or mixed hearing loss who receive an implantable bone-anchored hearing device with a percutaneous abutment or a partially implantable bone-anchored hearing device with transcutaneous coupling to the sound processor, the evidence includes observational studies that report pre-post differences in hearing parameters after treatment with BAHAs. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. No prospective trials were identified. Observational studies reporting on within-subjects changes in hearing have generally reported hearing improvements with the devices. Given the objectively measured outcomes and the largely invariable natural history of hearing loss in individuals who would be eligible for an implantable bone-conduction device, the demonstrated improvements in hearing after device placement can be attributed to the device. Studies of partially implantable bone-anchored devices have similarly demonstrated within-subjects improvements in hearing. The single-arm studies have shown improvements in hearing in the device-aided state. No direct comparisons other than within-individual comparisons with external hearing aids were identified, but, for individuals unable to wear an external hearing aid, there may be few alternative treatments. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

For individuals who have unilateral sensorineural hearing loss who receive a fully or partially implantable bone-anchored hearing device with contralateral routing of signal, the evidence includes 1 RCT, multiple prospective and retrospective case series, and a systematic review. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Single-arm case series, with sample sizes ranging from 9 to 145 patients, generally have reported improvements in patient-reported speech quality, speech perception in noise, and satisfaction with bone conduction devices with contralateral routing of signal. However, a well-conducted systematic review of studies comparing bone-anchored devices to hearing aids with contralateral routing of signal found no evidence of improvement in speech recognition or hearing localization. The single RCT included in the systematic review was a pilot study enrolling only 10 patients and, therefore, does not provide definitive evidence. The evidence is insufficient to determine the effects of the technology on health outcomes.

References
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016


Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016


Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016


Policy History
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016
06/11/2002 Medical Director review
06/20/2002 Medical Policy Committee review
06/24/2002 Managed Care Advisory Council approval. Format revision. No substance change to policy.
07/06/2004 Medical Director review
07/20/2004 Medical Policy Committee review. Format revision, Rationale/Source added to policy. No substance change to policy.
07/26/2004 Managed Care Advisory Council approval
06/07/2005 Medical Director review
06/21/2005 Medical Policy Committee review. Clinical criteria change. Coverage for single sided deafness and bilateral fittings added as investigational indication.
07/15/2005 Managed Care Advisory Council approval
06/13/2006 Format revisions. No changes to policy statement.
08/02/2006 Medical Director review
08/09/2006 Medical Policy Committee approval. Patient selection criteria updated to include age limitations.
10/10/2007 Medical Director review
10/17/2007 Medical Policy Committee approval. Policy statements updated and clarified related to eligibility for coverage for unilateral and bilateral sensorineural hearing loss. Policy statement added concerning investigational uses, including bilateral sensorineural hearing loss. Policy title changed to add “and Bone-Anchored”.
10/01/2008 Medical Director review
10/22/2008 Medical Policy Committee approval. No change to coverage eligibility.
10/01/2009 Medical Policy Committee approval
10/14/2009 Medical Policy Implementation Committee approval. No change to coverage eligibility.
10/14/2010 Medical Policy Committee review
10/20/2010 Medical Policy Implementation Committee approval. The age requirement in the coverage language changed to be consistent with FDA-approved labeling from “patients over five years of age” to “patients five years of age and older”. Coverage that stands alone without criteria placed under the subtitle “When Services Are Eligible for Coverage”.
02/01/2011 Coding updated
10/06/2011 Medical Policy Committee review
10/19/2011 Medical Policy Implementation Committee approval. Audiologic criteria revised to read:
- A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kHz of better than or equal to 45 dB (OBC and BP100 devices), 55 dB (Intenso device) or 65 dB (Cordele II device).
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

For bilateral implantation, patients should meet the above audiologic criteria, and have a symmetrically conductive or mixed hearing loss as defined by a difference between left and right side bone conduction threshold of less than 10 dB on average measured at 0.5, 1, 2 and 3 kHz, or less than 15 dB at individual frequencies.

10/11/2012 Medical Policy Committee review
10/31/2012 Medical Policy Implementation Committee approval. Added investigational statement for partially implantable hearing systems.
02/04/2013 Coding updated
10/03/2013 Medical Policy Committee review
10/16/2013 Medical Policy Implementation Committee approval. No change to coverage.
10/02/2014 Medical Policy Committee review
10/15/2014 Medical Policy Implementation Committee approval. No change to coverage.
10/08/2015 Medical Policy Committee review
10/21/2015 Medical Policy Implementation Committee approval. No change to coverage.
10/06/2016 Medical Policy Committee review
10/19/2016 Medical Policy Implementation Committee approval. Policy statements changed to remove investigational statement for partially implantable devices.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
Next Scheduled Review Date: 10/2017

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2015 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>69710, 69711, 69714, 69715, 69717, 69718</td>
</tr>
<tr>
<td>HCPCS</td>
<td>L8690, L8691, L8693</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>H60.399, H60.60-H60.63, H60.8X1-H60.8X9, H60.90-H60.93</td>
</tr>
<tr>
<td></td>
<td>H61.391-H61.399, H62.8X1-H62.8X9, H65.20-H65.23, H65.30-H65.33</td>
</tr>
</tbody>
</table>
Implantable Bone Conduction and Bone-Anchored Hearing Aids

Policy # 00004
Original Effective Date: 06/24/2002
Current Effective Date: 10/19/2016

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.